We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+29.44%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$215M
AUM Growth
+$17.5M
Cap. Flow
-$18.3M
Cap. Flow %
-8.51%
Top 10 Hldgs %
52.76%
Holding
47
New
10
Increased
10
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
AMAG
AMAG Pharmaceuticals
AMAG
+$9.06M
2
MDXG icon
MiMedx Group
MDXG
+$5.52M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$4.37M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.58M
5
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$3.43M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$10.4M
2
CMRX
Chimerix, Inc.
CMRX
+$9.53M
3
TVTX icon
Travere Therapeutics
TVTX
+$6.4M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$5.28M
5
GNMK
GenMark Diagnostics, Inc
GNMK
+$4.56M

Sector Composition

Rank Sector Weight
1 Healthcare 97.86%
2 Miscellaneous 2.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
26
Tvardi Therapeutics
TVRD
$24M
$3.17M 1.47%
8,750
+6,528
+294% +$2.47M
ZSPH
27
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$3.16M 1.47%
+75,000
New +$3.43M
IOVA icon
28
Iovance Biotherapeutics
IOVA
$3.74B
$2.42M 1.12%
+200,000
New +$2.25M
AXDX
29
DELISTED
Accelerate Diagnostics
AXDX
$2.26M 1.05%
10,060
+60
+0.6% +$12.5K
TENX icon
30
Tenax Therapeutics
TENX
$82M
$1.98M 0.92%
19
+5
+36% +$525K
EVOK
31
DELISTED
Evoke Pharma
EVOK
$1.73M 0.8%
1,701
+34
+2% +$30.7K
MGNX icon
32
MacroGenics
MGNX
$260M
$1.57M 0.73%
+50,000
New +$1.69M
BDSI
33
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.48M 0.68%
+140,500
New +$1.92M
CELGZ
34
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$1.46M 0.68%
490,000
-85,000
-15% -$269K
BLRX
35
BioLineRX
BLRX
$12.1M
$528K 0.25%
417
– –
NSPR icon
36
InspireMD
NSPR
$41.6M
– –
0
– –
TCON
37
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$171K 0.08%
+61
New +$160K
ALNY icon
38
Alnylam Pharmaceuticals
ALNY
$31.7B
– –
-29,100
Closed -$2.82M
CPRX
39
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-975,000
Closed -$2.9M
LAB icon
40
Standard BioTools
LAB
$256M
– –
-95,000
Closed -$3.2M
ARAV
41
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-39,167
Closed -$5.28M
PRTK
42
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-80,000
Closed -$3.08M
CSII
43
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-125,000
Closed -$3.76M
GNMK
44
DELISTED
GenMark Diagnostics, Inc
GNMK
– –
-335,000
Closed -$4.56M
HZNP
45
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-220,000
Closed -$2.84M
PCYC
46
DELISTED
PHARMACYCLICS INC
PCYC
– –
-85,000
Closed -$10.4M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2015 Portfolio in Review

As of Q1 2015, Opaleye Management held 47 positions worth $215M, up 8.8% from $198M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Opaleye Management withdrew a net $18.3M in Q1 2015, closing 10 positions and reducing 9 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 92% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in AMAG Pharmaceuticals worth $10.4M.

  • Opaleye Management's largest Q1 2015 buy was AMAG Pharmaceuticals: 190,000 shares worth $10.4M.
  • Opaleye Management added most to Neurocrine Biosciences in Q1 2015, an estimated $3.58M increase.
  • Opaleye Management's biggest Q1 2015 reduction was Chimerix, Inc., cutting an estimated $9.53M.
  • Opaleye Management fully exited PHARMACYCLICS INC in Q1 2015, selling an estimated $10.4M.
  • Opaleye Management's ten largest holdings make up 53% of its $215M portfolio in Q1 2015.
  • Opaleye Management opened 10 new positions and closed 10 in Q1 2015.
  • Opaleye Management's portfolio value rose 8.8% quarter-over-quarter to $215M.

Based on Opaleye Management's 13F filing for Q1 2015, filed 15 May 2015.